Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HS-10566 implant in high-risk non-muscle-invasive bladder cancer patients unable or unwilling to undergo radical cystectomy
CTR20261348Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10566 in bladder cancer, transitional cell carcinoma (TCC), non-muscle-invasive bladder cancer (NMIBC), sponsored by Hengrui Therapeutics. Started Apr 2026; status: active.
02
Drugs
HS-10566
03
Conditions
bladder cancertransitional cell carcinoma (TCC)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20261348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261348.